Restricted accessResearch articleFirst published online 2017-5
In vitro evaluation of an injectable biphasic calcium phosphate (BCP) carrier system combined with recombinant human bone morphogenetic protein (rhBMP)-9
Bone morphogenetic protein 9 (BMP9) has previously been characterized as the strongest osteoinductive growth factor among the BMP family. The aim of the present study was to evaluate the possibility of combining rhBMP9 with an injectable biphasic calcium phosphate (I-BCP, maxresorb inject®), since I-BCP is an easy to handle biomaterial with ideal properties for bone augmentation procedures. The adsorption potential of rhBMP9 as well as the cell behavior of bone stromal ST2 cells were investigated on cell viability, adhesion, proliferation and osteogenic differentiation for I-BCP combined with/without rhBMP9 in vitro. I-BCP demonstrated excellent adsorption/retention potential of rhBMP9 with a slow and steady release over a 10 day period by ELISA. Cell attachment at 8 hours and cell proliferation at 1, 3 and 5 days was decreased on I-BCP with/without rhBMP9 when compared to control tissue-culture plastic. While I-BCP had little influence on osteoblast differentiation, its combination with rhBMP9 significantly increased ALP activity at 7 days and mRNA levels of osteoblast differentiation markers including ALP and osteocalcin at 14 days. I-BCP served as an excellent carrier for rhBMP9 clearly demonstrating its osteoinductive potential. We therefore confirm the great potential of rhBMP9 to serve as a future regenerative growth factor for bone applications.
MillerA.F.HarveyS.A.ThiesR.S. and OlsonM.S., Bone morphogenetic protein-9. An autocrine/paracrine cytokine in the liver, J Biol Chem275(24) (2000), 17937–17945. doi:10.1074/jbc.275.24.17937.
2.
SongJ.J.CelesteA.J.KongF.-M.JirtleR.L.RosenV. and ThiesR.S., Bone morphogenetic protein-9 binds to liver cells and stimulates proliferation, Endocrinology136(10) (1995), 4293–4297.
3.
LuuH.H.SongW.X.LuoX.ManningD.LuoJ.DengZ.L.et al., Distinct roles of bone morphogenetic proteins in osteogenic differentiation of mesenchymal stem cells, J Orthop Res25(5) (2007), 665–677. doi:10.1002/jor.20359.
4.
LuoJ.TangM.HuangJ.HeB.C.GaoJ.L.ChenL.et al., TGFbeta/BMP type I receptors ALK1 and ALK2 are essential for BMP9-induced osteogenic signaling in mesenchymal stem cells, J Biol Chem285(38) (2010), 29588–29598. doi:10.1074/jbc.M110.130518.
5.
LamplotJ.D.QinJ.NanG.WangJ.LiuX.YinL.et al., BMP9 signaling in stem cell differentiation and osteogenesis, Am J Stem Cells2(1) (2013), 1–21.
6.
ChengH.JiangW.PhillipsF.M.HaydonR.C.PengY.ZhouL.et al., Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs), J Bone Joint Surg Am85(8) (2003), 1544–1552. doi:10.2106/00004623-200308000-00017.
7.
KangQ.SunM.H.ChengH.PengY.MontagA.DeyrupA.et al., Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery, Gene therapy11(17) (2004), 1312–1320. doi:10.1038/sj.gt.3302298.
8.
Fujioka-KobayashiM.SawadaK.KobayashiE.SchallerB.ZhangY. and MironR.J., Recombinant human bone morphogenetic protein 9 (rhBMP9) induced osteoblastic behaviour on a collagen membrane compared with rhBMP2, Journal of periodontology87(6) (2016), e101–e107.
9.
Fujioka-KobayashiM.SawadaK.KobayashiE.SchallerB.ZhangY. and MironR.J., Osteogenic potential of rhBMP9 combined with a bovine-derived natural bone mineral scaffold compared to rhBMP2, Clinical Oral Implants Research (2016).
10.
MironR.J. and ZhangY.F., Osteoinduction: A review of old concepts with new standards, J Dent Res91(8) (2012), 736–744. doi:10.1177/0022034511435260.
11.
DaculsiG.LabouxO.MalardO. and WeissP., Current state of the art of biphasic calcium phosphate bioceramics, Journal of Materials Science: Materials in Medicine14(3) (2003), 195–200.
12.
DaculsiG., Biphasic calcium phosphate concept applied to artificial bone, implant coating and injectable bone substitute, Biomaterials19(16) (1998), 1473–1478. doi:10.1016/S0142-9612(98)00061-1.
13.
ArinzehT.L.TranT.McalaryJ. and DaculsiG., A comparative study of biphasic calcium phosphate ceramics for human mesenchymal stem-cell-induced bone formation, Biomaterials26(17) (2005), 3631–3638. doi:10.1016/j.biomaterials.2004.09.035.
14.
RoldanJ.DetschR.SchaeferS.ChangE.KelantanM.WaissW.et al., Bone formation and degradation of a highly porous biphasic calcium phosphate ceramic in presence of BMP-7, VEGF and mesenchymal stem cells in an ectopic mouse model, Journal of Cranio-Maxillofacial Surgery38(6) (2010), 423–430. doi:10.1016/j.jcms.2010.01.003.
15.
SchopperC.MoserD.SpassovaE.GoriwodaW.LagogiannisG.HoeringB.et al., Bone regeneration using a naturally grown HA/TCP carrier loaded with rh BMP-2 is independent of barrier-membrane effects, Journal of Biomedical Materials Research Part A85(4) (2008), 954–963. doi:10.1002/jbm.a.31525.
16.
DimarJ.R.GlassmanS.D.BurkusK.J. and CarreonL.Y., Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/compression resistant matrix versus iliac crest bone graft, Spine31(22) (2006), 2534–2539. doi:10.1097/01.brs.0000240715.78657.81.
17.
MironR.J.BosshardtD.D.BuserD.ZhangY.TuguluS.GemperliA.et al., Comparison of the capacity of enamel matrix derivative gel and enamel matrix derivative in liquid formulation to adsorb to bone grafting materials, J Periodontol86(4) (2015), 578–587. doi:10.1902/jop.2015.140538.
18.
ZhangY.YangS.ZhouW.FuH.QianL. and MironR.J., Addition of a synthetically fabricated osteoinductive biphasic calcium phosphate bone graft, to BMP2 improves new bone formation, Clinical implant dentistry and related research, 2015.
19.
MironR.J.BosshardtD.D.GemperliA.C.DardM.BuserD.GruberR.et al., In vitro characterization of a synthetic calcium phosphate bone graft on periodontal ligament cell and osteoblast behavior and its combination with an enamel matrix derivative, Clinical oral investigations18(2) (2014), 443–451. doi:10.1007/s00784-013-0977-4.
20.
SawadaK.Caballe-SerranoJ.BosshardtD.D.SchallerB.MironR.J.BuserD.et al., Antiseptic solutions modulate the paracrine-like activity of bone chips: Differential impact of chlorhexidine and sodium hypochlorite, J Clin Periodontol (2015).
21.
Fujioka-KobayashiM.SawadaK.KobayashiE.SchallerB.ZhangY. and MironR.J., Osteogenic potential of rhBMP9 combined with a bovine-derived natural bone mineral scaffold compared to rhBMP2, Clin Oral Implants Res (2016).
22.
MironR.J.HedbomE.SaulacicN.ZhangY.SculeanA.BosshardtD.D.et al., Osteogenic potential of autogenous bone grafts harvested with four different surgical techniques, J Dent Res90(12) (2011), 1428–1433. doi:10.1177/0022034511422718.
23.
Fujioka-KobayashiM.SchallerB.ZhangY.KandalamU.HernandezM. and MironR.J., Recombinant human bone morphogenetic protein (rhBMP)9 induces osteoblast differentiation when combined with demineralized freeze-dried bone allografts, (DFDBAs) or biphasic calcium phosphate (BCP), Clin Oral Investig (2016).
24.
CarreiraA.C.LojudiceF.H.HalcsikE.NavarroR.D.SogayarM.C. and GranjeiroJ.M., Bone morphogenetic proteins: Facts, challenges, and future perspectives, J Dent Res93(4) (2014), 335–345. doi:10.1177/0022034513518561.
25.
RocqueB.G.KellyM.P.MillerJ.H.LiY. and AndersonP.A., Bone morphogenetic protein-associated complications in pediatric spinal fusion in the early postoperative period: An analysis of 4658 patients and review of the literature, Journal of neurosurgery Pediatrics14(6) (2014), 635–643. doi:10.3171/2014.8.PEDS13665.
26.
HaidarZ.S.HamdyR.C. and TabrizianM., Delivery of recombinant bone morphogenetic proteins for bone regeneration and repair. Part A: Current challenges in BMP delivery, Biotechnology letters, 31(12) (2009), 1817–1824.
27.
PerriB.CooperM.LauryssenC. and AnandN., Adverse swelling associated with use of rh-BMP-2 in anterior cervical discectomy and fusion: A case study, The Spine Journal7(2) (2007), 235–239. doi:10.1016/j.spinee.2006.04.010.
28.
GarrettM.P.KakarlaU.K.PorterR.W. and SonntagV.K., Formation of painful seroma and edema after the use of recombinant human bone morphogenetic protein-2 in posterolateral lumbar spine fusions, Neurosurgery66(6) (2010), 1044–1049. doi:10.1227/01.NEU.0000369517.21018.F2.
